NFNina la Cour Freiesleben

Nina la Cour Freiesleben

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nina la Cour Freiesleben has a total of 278 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Does intracytoplasmic sperm injection outperform conventional in vitro fertilization in couples without severe male factor infertility? A systematic review and meta-analysis of randomized controlled trials

    by Kailibinuer Kayimu, Sine Berntsen, Yu Fu, Yi Yuan, Kilian Vomstein, Tian Tian, Fang Liu, Jiayi Gao, Lan N Vuong, Tuong M Ho, et al.

    STUDY QUESTION: Does ICSI improve the live birth rate in couples without severe male factor infertility compared to conventional IVF (cIVF)? SUMMARY ANSWER: High-quality evidence showed no benefit of ICSI over cIVF in improving live birth or cumulative live birth rates among couples without severe male factor infertility. WHAT IS KNOWN ALREADY: Although ICSI is an effective method within ART for severe male factor infertility, it is frequently used for other infertility etiologies despite insufficient evidence. The effectiveness of ICSI compared with cIVF in couples with mild male or without severe male factor infertility remains uncertain. STUDY DESIGN, SIZE, DURATION: Systematic review and meta-analysis. PubMed, EMBASE, MEDLINE, Web of Science, Cochrane Library, ProQuest Dissertations & Theses Global, Scopus, CINAHL Plus, Chinese Wan Fang, and CNKI databases were searched from inception to 31 May 2025 without language restrictions. The search strategy encompassed three key domains: ICSI, cIVF, and ART treatment outcomes. PARTICIPANTS/MATERIALS, SETTING, METHODS: We included randomized controlled trials (RCTs) comparing outcomes of ICSI versus cIVF per couple. Exclusion criteria were duplicate studies, conference abstracts or proceedings, trial registry records, editorials, letters, non-randomized designs, RCTs that did not randomize participants to ICSI or cIVF, studies comparing effects per oocyte rather than per couple, studies lacking complete outcome data, and those not meeting predefined criteria for trustworthiness. Study characteristics and ART outcomes were extracted. The risk of bias and study trustworthiness were independently evaluated by two investigators using the Cochrane Collaboration’s Risk of Bias 2 Tool and TRACT checklist, respectively. GRADE decision-making was used to evaluate the quality of evidence. MAIN RESULTS AND THE ROLE OF CHANCE: Six RCTs reporting on couples without severe male factor infertility were included. The meta-analysis showed no benefit from ICSI over cIVF in live birth rate (four studies, N = 1438, 32.8% vs 34.5%, pooled risk ratio (RR) = 0.96, 95% CI: 0.85–1.09, I2 = 37%, high-quality evidence) or cumulative live birth rate (three studies, N = 1911, 43.2% vs 47.4%, pooled RR = 0.92, 95% CI: 0.84–1.01, I2 = 41%, high-quality evidence). ICSI was associated with a lower preterm birth rate (three studies, N = 222, 4.6% vs 6.0%, pooled RR = 0.77, 95% CI: 0.59–1.00, P = 0.0447, I2 = 0, high-quality evidence). No significant differences were observed for other fertility or pregnancy outcomes. LIMITATIONS, REASONS FOR CAUTION: The findings should be interpreted with caution due to the limited number of high-quality studies reporting live birth data, limited subgroup-specific evidence, and some heterogeneity in outcome measures. WIDER IMPLICATIONS OF THE FINDINGS: Evidence from this meta-analysis shows no advantage of ICSI over cIVF in improving live birth or cumulative live birth rates among couples without severe male factor infertility. Based on current evidence, ICSI should not be routinely recommended for indications other than severe male infertility. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by the National Natural Science Foundation of China (No. 82204052), the National Key Research and Development Program of China (No. 2022YFC2703102), and Peking University Third Hospital (No. BYSYDL2022001, BYSYDL2024003) with salaries for J.Q., Y.W., K.K., Y.F., Y.Y., T.T., F.L., and J.G. The funders of the study played no role in study design, data collection, data analysis, data interpretation, or writing of the report. S.B. has received scientific grants from Gedeon Richter and Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis’ Fond. K.V. has received speakers’ fees from Gedeon Richter, Merck, and IBSA. L.N.V. has received grants, speakers’ fees, and conference fees (including travel support) from Merck Sharp & Dohme, and Ferring, and scientific board fees from Ferring. T.M.H. has received speakers’ fees from Merck, Merck Sharp & Dohme, and Ferring. A.P. has received speakers’ fees (including those classified as honoraria) from Ferring Pharmaceuticals, Merck, Gedeon Richter, IBSA, Abbott and Consulting fees from Gedeon Richter and Ferring and travel support from Gedeon Richter. H.S.N. received speakers’ fees from Ferring Pharmaceuticals, Merck, Astra Zeneca, Cook Medical, Gedeon Richter, Ibsa Nordic, Novo Nordisk, and Bessins. B.W.M. reports consulting fees, travel support, and research funding from Merck and consulting fees from Ferring, Organon, Repronovo, UNILAB, Vitra, and Norgine. N.l.C.F. has received speakers’ fees from Merck and Ferring Pharmaceuticals, consulting fees from Merck, and meeting support/registration fees from Merck, Ferring Pharmaceuticals, IBSA, and Gedeon Richter (paid to institution). She is also an unpaid chair in the steering committee for the guideline groups of The Danish Fertility Society. All other authors declare no competing interests REGISTRATION NUMBER: CRD42023479967.


  • Ovarian and reproductive hormone characteristics and risk of cycle cancellation in immediate versus postponed modified natural cycle frozen embryo transfer (mNC-FET) cycles

    by Sara Bergenheim, Amalie Somuncu Johansen, Clara Colombo, Marte Saupstad, Tine Vrist Dam, Jeanette Wulff Bogstad, Nina la Cour Freiesleben, Lisbeth Prætorius, Ida Behrendt-Møller, Birgitte Oxlund-Mariegaard, et al.

    Do ovarian and reproductive hormone characteristics and risk of cycle cancellation differ between immediate and postponed modified natural cycle (mNC) frozen embryo transfer (FET) cycles? Ovarian morphology, early follicular phase levels of progesterone and LH, and follicular phase length differed significantly between immediate and postponed mNC-FET. Cancellation rates differed numerically. The optimal timing of mNC-FET following ovarian stimulation and oocyte retrieval is heavily debated. Concerns about suboptimal ovarian and hormonal conditions in the NC immediately following ovarian stimulation have led to the widespread practice of postponing FET for at least 1 month. However, emerging evidence suggests that reproductive outcomes in immediate programmed FET cycles are comparable, or even superior, to those achieved in postponed cycles. Studies of the NC immediately following ovarian stimulation and oocyte retrieval are lacking, leaving a limited understanding of its functionality, cycle characteristics, hormonal profiles, and ovarian morphology. This descriptive study is based on data from a recently completed Danish multicentre randomised controlled non-inferiority trial (RCT) evaluating the optimal timing of FET following ovarian stimulation and oocyte retrieval. Women were randomised 1:1 to mNC-FET in the cycle immediately following ovarian stimulation and oocyte retrieval, or after a 1-month delay. Data from 468 women, collected from March 2021 to May 2025, were included in this study. Women with a regular menstrual cycle, aged 18–40 years, and undergoing autologous single blastocyst mNC-FET were eligible for inclusion. The presence of cystic intraovarian structures > 10 mm and plasma levels of FSH, LH, estradiol, and progesterone from cycle initiation to blastocyst transfer were assessed, as were the length of the follicular phase and cancellation rates between groups. The number of cystic ovarian structures was significantly higher in the immediate group than in the postponed group on Days 2–5 of the treatment cycle (median, 3 [IQR, 1–6] vs 0 [IQR, 0–1]; P < 0.001) as well as on the day of ovulation trigger (median, 1 [IQR, 0–2] vs 0 [IQR, 0–1]; P < 0.001). In the early follicular phase, plasma progesterone levels were higher (median, 1.2 [IQR, 0.7–1.7] vs 0.8 [IQR, 0.6–1.5] nmol/L; P < 0.001) in the immediate compared to postponed cycles, and plasma LH levels were lower (median, 4.1 [IQR, 2.7–6.1] vs 5.9 [IQR, 4.7–7.5] IU/L; P < 0.001), as were FSH levels (median, 6.6 [IQR, 5.0–8.2] vs 6.9 [IQR, 5.9–7.9] IU/L; P = 0.047). The time to ovulation trigger was longer in the immediate than in the postponed group (mean, 15.0 [SD, 3.9] vs 13.0 [SD, 3.0] days; P < 0.001): an effect driven by freeze-all cycles. As a natural consequence of the increased time to ovulation trigger, more follicular scans were performed in the immediate group (median, 3 [IQR, 2–3] vs 2 [IQR, 1–3]; P < 0.001). Cycle cancellation was more frequent in immediate cycles, however, the difference was not statistically significant (10.3% vs 6.2%; P = 0.078). The main endpoints of this study were specified in the study protocol of the RCT, but some post hoc analyses were performed to explore unexpected findings. Due to variations in clinical practice, data were subjected to multiple subdivisions. No power calculations were performed for the reported endpoints. The follicular phase of immediate cycles seems to differ from postponed cycles in terms of ovarian morphology, follicular phase length, and early follicular phase levels of progesterone and LH. The rate of cycle cancellation raises concerns about the clinical feasibility of immediate FET treatment in NCs. The RCT is supported by Rigshospitalet’s Research Foundation and an independent research grant from Merck A/S (MS200497_0024). Merck A/S had no role in the design of this study and will not have any role during its execution, analyses, interpretation of data, or decision to submit results. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors. S.B. and C.C. benefitted from a grant from Merck A/S. S.B. is currently employed by Novo Nordisk. M.S. benefitted from a grant from Gedeon Richter and received support for meeting attendance from the same. M.S. received payment for lectures from IBSA and Gedeon Richter. J.W.B. received support from meeting attendance from Merck A/S, Ferring Pharmaceuticals, and Gedeon Richter. N.C.F. received consulting fees and honoraria for a presentation from Merck A/S and Ferring Pharmaceuticals and support for meeting attendance from Merck A/S, Ferring Pharmaceuticals, IBSA, and Gedeon Richter. N.C.F. is chair of the steering committee for the guideline groups for The Danish Fertility Society. L.P. received support for meeting attendance from Merck A/S, Ferring Pharmaceuticals, and Gedeon Richter. L.P. declare stocks in Novo Nordisk. B.O.-M. received support for meeting attendance from Gedeon Richter and Ferring Pharmaceuticals and participate on a board for Ferring Pharmaceuticals. B.N. benefitted from grants from Merck A/S and Gedeon Richter. B.N. received support for meeting attendance from Gedeon Richter and participate on a board for Ferring Pharmaceuticals. E.L. received honoraria from Pfizer and Gedeon Richter, and support for meeting attendance from Gedeon Richter, Merck A/S, and Astellas. A.P. received grants from Gedeon Richter, Ferring Pharmaceuticals, and Merck A/S as payment to the institution. A.P. received consulting fees from Ferring Pharmaceuticals, Gedeon Richter, and Merck A/S, and honoraria from Ferring Pharmaceuticals, Gedeon Richter, Abbott, and Merck A/S. K.L. received a grant from Gedeon Richter as payment to the institution. K.L. received consulting fees and honoraria from Ferring Pharmaceuticals and support for attending meetings from Ferring Pharmaceuticals, Gedeon Richter, and Merck A/S. A.S.J., T.V.D., I.B.-M., M.H., and N.S. declare no conflicts of interest. The study is registered at ClinicalTrials.gov: NCT04748874.

  • Early embryo developmental kinetics following IVF versus ICSI in patients without severe male factor infertility: a secondary analysis of a multicentre, randomized controlled trial (INVICSI)

    by Sine Berntsen, Anne Zedeler, Marie Louise Grøndahl, Anette Vestergaard Gabrielsen, Morten Rønn Petersen, Dea Frøding Skipper, Bugge Nøhr, Anne Lis Englund, Ellen Løkkegaard, Lisbeth Prætorius, et al.

    STUDY QUESTION: Are there any differences in embryo development and morphokinetics between ICSI and conventional IVF (c-IVF) in first cycle patients without severe male factor infertility? SUMMARY ANSWER: ICSI resulted in fewer usable and high-quality blastocysts on Day 5 compared to c-IVF, with no observed differences in morphokinetics or cleavage patterns among patients without severe male factor infertility. WHAT IS KNOWN ALREADY: Recent randomized controlled trials (RCTs) comparing ICSI and c-IVF have found that ICSI does not improve live birth rates compared to c-IVF when there is no severe male factor. Data on embryo development and morphokinetics between ICSI and c-IVF are lacking. STUDY DESIGN, SIZE, DURATION: This was a secondary analysis of an open-label, multicentre, RCT comparing ICSI and c-IVF in 824 patients without severe male factor infertility, with participants recruited between 29 November 2019 and 14 December 2022. In this secondary study, we aimed to explore potential differences in embryo development between ICSI and c-IVF by using registered data on embryo quality and destiny, along with time-lapse data on embryo morphokinetics and cleavage patterns. All analyses were carried out comparing per protocol results between the ICSI group and the c-IVF group. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligible participants were women with a male partner who did not have severe male factor infertility, defined as a minimum of 2 million progressively motile spermatozoa, and women/couples using donor sperm. Data were collected on all retrieved oocytes from the study cycles, along with information on embryo development and utilization. Additionally, time-lapse data were extracted and analysed from three trial sites, allowing for the evaluation of morphokinetic parameters and cleavage patterns. MAIN RESULTS AND THE ROLE OF CHANCE: The analysis included 388 participants in the ICSI group and 378 in the c-IVF group. There was no significant difference in the number of retrieved oocytes between the two groups. Compared to c-IVF, ICSI resulted in fewer 1PN and >2PN embryos. However, ICSI was also associated with fewer cleaved embryos on Day 2, lower total number of blastocysts, fewer blastocysts utilized for transfer or vitrification, and fewer high-quality blastocysts on Day 5 (based on Gardner’s criteria) (P < 0.05 for all). No significant differences were observed in the number of high-quality embryos on Day 2, high-quality blastocysts on Day 6 or vitrified Day 6 blastocysts. Blastocyst quality in the first embryo transfer did not differ between groups. The time-lapse imaging subgroup analysis included 482 participants (247 in the ICSI group and 235 in the c-IVF group), and assessment of 1846 ICSI-treated and 1900 c-IVF-treated oocytes. When accounting for an expected c-IVF delay, there were no differences in timing of embryo development between ICSI and c-IVF. No significant differences were found in the incidence of multinucleation at the two-cell or four-cell stage, direct cleavage, rolling or reverse cleavage. LIMITATIONS, REASONS FOR CAUTION: Traditional sperm parameters, including sperm count and motility, were used in this study. We did not assess sperm DNA fragmentation or other advanced sperm characteristics, which have been suggested to influence early embryonic development. WIDER IMPLICATIONS OF THE FINDINGS: This is the first study based on data from a randomized trial in which patients were assigned to either ICSI or c-IVF to examine the effect of fertilization method on embryo morphokinetics, cleavage patterns and blastocyst formation. ICSI resulted in fewer available blastocysts and high-quality blastocysts on Day 5 compared to c-IVF, while most other outcomes were comparable between groups. These findings are clinically relevant and add to the growing body of evidence that ICSI should not be preferred over c-IVF in the absence of severe male factor infertility. STUDY FUNDING/COMPETING INTEREST(S): The INVICSI study was supported by an unrestricted grant from Gedeon Richter (to S.B.) and funded by the Capital Region of Denmark (A6606), Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis’ Legat (4101466; to S.B.) and Amager/Hvidovre Hospital. The funders had no involvement in the study design, data collection, analysis, interpretation of results, manuscript preparation or the decision to submit the manuscript for publication. S.B. has received a grant from Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis’ Fond outside the current work. A.P. has received grants from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S and Cryos, all paid to her institution; consulting fees from IBSA, Ferring Pharmaceuticals, Gedeon Richter, Merck A/S and Cryos; honoraria from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S and Organon; and travel support from Gedeon Richter (paid directly to institution). M.L.G. has received grants from Gedeon Richter (via her institution) and Merck, and consulting fees from Cooper Surgical. B.N. has received grants from Gedeon Richter, Merck, and Ferring, all paid to his institution, and has received support for attending meetings and/or travel from Gedeon Richter and Merck. N.L.C.F. has received grants from Gedeon Richter, Merck and Cryos (all paid to her institution); consulting fees from Merck; and support for attending meetings from Gedeon Richter, Merck, Ferring Pharmaceuticals and IBSA. E.L. has received honoraria from Pfizer (lecture), hospital compensation from Radiometer (equipment validation) and support for attending meetings and/or travel from Gedeon Richter and Merck. She also serves on the advisory board for Astellas Pharma Nordic. H.S.N. has received grants from Freya Biosciences, Ferring Pharmaceuticals, BioInnovation Institute, Ministry of Education, Novo Nordisk Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, Independent Research Fund Denmark and Ole...


  • Open Access

    Efficacy of clindamycin and LACTIN-V for in vitro fertilization patients with vaginal dysbiosis: a randomised double-blind, placebo-controlled multicentre trial

    by Thor Haahr, Nina la Cour Freiesleben, Mette Brix Jensen, Helle Olesen Elbaek, Birgit Alsbjerg, Rita Laursen, Lisbeth Prætorius, Henriette Svarre Nielsen, Anja Pinborg, Vibeke Hartvig Boujida, et al.

    The primary aim of the present randomised, double-blind, placebo-controlled trial was to investigate whether clindamycin and live Lactobacillus crispatus CTV-05 (LACTIN-V) would improve clinical pregnancy rates in IVF patients with abnormal vaginal microbiota (AVM) defined by high quantitative PCR loads of Fannyhessea vaginae and Gardnerella spp. IVF patients were randomised prior to embryo transfer into three parallel groups 1:1:1. Group one (CLLA) received clindamycin 300 mg ×2 daily for 7 days followed by vaginal LACTIN-V until the day of pregnancy scan. Group two (CLPL) received clindamycin and placebo LACTIN-V, and finally, group three (PLPL) received an identical placebo of both drugs. A total of 1533 patients were screened, and 338 patients were randomised. The clinical pregnancy rates per embryo transfer were 42% (95%CI 32-52%), 46% (95%CI 36-56%) and 45% (95%CI 35-56%) in the CLLA, CLPL, PLPL groups respectively. Thus, treatment of AVM did not improve reproductive outcome. The EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) clinical trial identifier is 2016-002385-31; first registration day 2016-07-11.


  • Open Access

    IVF versus ICSI in patients without severe male factor infertility: a randomized clinical trial

    by Sine Berntsen, Anne Zedeler, Bugge Nøhr, Morten Rønn Petersen, Marie Louise Grøndahl, Lars Franch Andersen, Kristine Løssl, Ellen Løkkegaard, Anne Lis Englund, Anette Vestergaard Gabrielsen, et al.

    Intracytoplasmic sperm injection (ICSI) and conventional in vitro fertilization (c-IVF) are widely used fertilization techniques in assisted reproduction, but their relative effectiveness in patients without severe male factor infertility remains debated. While ICSI’s role in couples with severe male factor infertility is well established, its routine use in cases with normal or nonseverely decreased sperm quality is not evidence-based. Here we conducted the INVICSI study, an open-label, multicenter randomized controlled trial, to compare cumulative live birth rates (CLBR) as the primary outcome between ICSI and c-IVF in patients without severe male factor infertility. Between November 2019 and December 2022, 824 women undergoing their first IVF cycle were randomized to ICSI (n = 414) or c-IVF (n = 410) across six public fertility clinics in Denmark. The CLBR was 43.2% (179/414) in the ICSI group and 47.3% (193/408) in the c-IVF group, yielding a risk ratio of 0.91 (95% confidence interval, 0.79–1.06). These findings demonstrate that ICSI does not improve CLBR compared to c-IVF and support c-IVF as the preferred first-line treatment for patients with normal or nonseverely decreased sperm quality. ICSI should be reserved for severe male factor infertility. ClinicalTrials.gov registration: NCT04128904.


  • Open Access

    Maternal-Fetal Outcomes and Antibody Transfer, Depending on the Trimester of SARS-CoV-2 Infection in Non-Vaccinated Women—A Danish Nationwide Prospective Cohort Study

    by Line Fich, Ann-Marie Hellerung Christiansen, Kathrine Vauvert R. Hviid, Anna J. M. Aabakke, Eva Hoffmann, Andreas Ingham, Joaquim Ollé-López, Judith Bello-Rodríguez, Helle Gybel Juul-Larsen, Louise Kelstrup, et al.

    Passive maternal-fetal transfer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies has been demonstrated, whilst the degree of transfer depending on the trimester of infection is lacking. Due to neonates’ immature immune systems, this knowledge could be of interest when investigating the degree of early-life protection against SARS-CoV-2. For perinatal infections such as Rubella and Toxoplasmosis, the timing of infection related to gestational age is crucial for the severity of maternal-fetal outcomes; hence, the trimester of SARS-CoV-2 infection could potentially be crucial. So far, there is no stratification on all three trimesters of SARS-CoV-2 infection in relation to maternal antibody levels in SARS-CoV-2 positive women, and the degree of transfer of SARS-CoV-2 antibodies to the newborn nor on obstetric and neonatal outcomes, which we examined in this study. Eleven departments in Denmark invited women who tested SARS-CoV-2 positive during pregnancy to participate with a blood sample and a cord blood sample at delivery. 459 SARS-CoV-2 positive women and 2567 SARS-CoV-2 negative women were included. A percentage of 87.5%, 95.3%, and 60.3% of newborns of women who tested positive in their first, second, and third trimester, respectively, had a significantly higher immunoglobin G (IgG) antibody level than their mother at delivery, indicating that the fetus is able to concentrate antibody levels or maintain the level of IgG antibodies transferred. None of the examined maternal-fetal outcomes were increased in women infected with SARS-CoV-2.


  • Psychosocial and physical wellbeing in women and male partners undergoing immediate versus postponed modified natural cycle frozen embryo transfer after ovarian stimulation and oocyte pick-up: a sub-study of a randomized controlled trial

    by Sara Bergenheim, Marte Saupstad, Clara Colombo, Julie Elkjær Møller, Jeanette Wulff Bogstad, Nina la Cour Freiesleben, Ida Behrendt-Møller, Lisbeth Prætorius, Birgitte Oxlund, Bugge Nøhr, et al.

    STUDY QUESTION: Are there differences in psychosocial and physical wellbeing among women and male partners undergoing modified natural cycle (mNC) frozen embryo transfer (FET) in immediate compared to postponed cycles after ovarian stimulation (OS) and oocyte pick-up (OPU)? SUMMARY ANSWER: Significantly more women in the immediate group reported physical symptoms than women in the postponed group whilst fewer were emotionally affected by waiting time, although the latter difference lost statistical significance after adjustment for multiple testing. WHAT IS KNOWN ALREADY: Infertility and fertility treatment are known to cause psychosocial distress in women and couples longing for a child. The treatment may be long-term and delayed for various reasons, such as the elective postponement of FET after a fresh transfer without pregnancy or an elective freeze-all cycle, possibly further increasing the level of distress. STUDY DESIGN, SIZE, DURATION: Sub-study of an ongoing multicentre randomized controlled, non-inferiority trial assessing the optimal timing for mNC-FET treatment after OS and OPU. Participants were randomized 1:1 to mNC-FET in the cycle immediately following OS or mNC-FET in a subsequent cycle. The study is based on data from the first women (N = 300) and male partners (N = 228) invited to answer a self-reported questionnaire assessing psychosocial and physical wellbeing. Data were collected from April 2021 to March 2024. PARTICIPANTS/MATERIALS, SETTING, METHODS: Questionnaires were distributed to all randomized women and their male partners on cycle day 2–5 of mNC-FET cycles and returned before the administration of ovulation trigger. The questionnaire consisted of validated items originating from the Copenhagen Multicentre Psychosocial Infertility—Fertility Problem Stress Scale (COMPI-FPSS) and Marital Benefit Measure (COMPI-MBM). Emotional reactions to waiting time in fertility treatment, mental health, general quality-of-life, and physical symptoms were also assessed. MAIN RESULTS AND THE ROLE OF CHANCE: Questionnaire response rates were 90.3% for women and 80.0% for male partners in the immediate group, and 82.3% for women and 57.3% for male partners in the postponed group. Approximately 90% of all women worried to some or a great extent about whether the treatment would be successful. More women in the postponed group reported that they were emotionally affected by the waiting time from OPU to blastocyst transfer to some or to a great extent (57.4% versus 73.9% in the immediate versus postponed group, P = 0.014), but the results were not significant after adjustment for multiple testing (P = 0.125). For male partners, no difference in emotional reactions to waiting time between groups was found. There was no significant difference in total infertility-related stress or symptoms of severe depression between the immediate and the postponed group for women or male partners, but women were generally more distressed than their partners. There was a significantly higher incidence of stomach and/or pelvic pain (24.0% versus 9.4%, adjusted P = 0.013), feeling of being bloated (33.8% versus 15.1%, adjusted P = 0.010) and swollen or tender breasts (24.8% versus 0.9%, P < 0.001) in the immediate group. LIMITATIONS, REASONS FOR CAUTION: All items were self-reported. No assessment of psychosocial or physical wellbeing was performed before participant enrolment. The sample size of male partners was relatively small, and female partners were not included in this sub-study due to a very small number of participants in this group. WIDER IMPLICATIONS OF THE FINDINGS: If immediate mNC-FET proves to be effective, physical and emotional factors may play a key role in choosing treatment strategy for the individual patient. This study demonstrated more physical symptoms related to OS in the immediate cycles. STUDY FUNDING/COMPETING INTEREST(S): The RCT was supported by Rigshospitalet’s Research Foundation and an independent research grant from Merck A/S (MS200497_0024). Merck A/S had no role in the design of this study and will not have any role during its execution, analyses, interpretation of data, or decision to submit results. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors. A.P. received grants from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S and Cryos as payment to the institution. A.P. received consulting fees from IBSA, Ferring Pharmaceuticals, Gedeon Richter, Cryos and Merck A/S, and honoraria from Organon, Ferring Pharmaceuticals, Gedeon Richter and Merck A/S. A.P. received support for meeting attendance from Gedeon Richter. M.S. benefitted from a grant from Gedeon Richter. S.B. and C.C. benefitted from a grant from Merck A/S. S.B. is currently employed by Novo Nordisk. N.C.F. received grants from Gedeon Richter, Merck A/S and Cryos as payment to the institution. N.C.F. received consulting fees from Merck A/S and support for meeting attendance from Merck A/S, Ferring Pharmaceuticals, IBSA, and Gedeon Richter. N.C.F. is chair of the steering committee for the guideline groups for The Danish Fertility Society. E.L. received a radiometer contract on blood gas validation as a payment to the institution. E.L. received honoraria from Pfizer and support for meeting attendance from Astella. B.N. received grants from IBSA, Ferring Pharmaceuticals, Merck A/S, and Gedeon Richter as payment to the institution. B.N. received honoraria from Merck A/S and Organon and support for meeting attendance from IBSA and Gedeon Richter. B.N. and L.P. participate in an Advisory Board at Ferring Pharmaceuticals. L.P. received support for meeting attendance from Merck A/S, Ferring Pharmaceuticals, and Gedeon Richter. L.P. declare stocks in Novo Nordisk. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT04748874


  • Open Access

    Vaginal Microbiota Transplantation (VMT) for treatment of vaginal dysbiosis without the use of antibiotics – A Double-Blinded Randomized Controlled Trial in healthy women with vaginal dysbiosis

    by Tine Wrønding, Kilian Vomstein, Kevin DeLong, Agnete Troen Lundgaard, Sarah Mollerup, Brynjulf Mortensen, Elleke F. Bosma, Ann Marie Hellerung, Emilie Vester Engel, Klara Dortea Wiil, et al.

    Here we describe the first double-blinded, randomized, placebo-controlled trial (RCT) on vaginal microbiota transplantation (VMT) without antibiotics in women with both symptomatic and asymptomatic vaginal dysbiosis. Forty-nine women were randomly assigned to VMT or placebo. The trial did not show a significant conversion to our predefined Lactobacillus -dominated microbiome. However, in participants not initially converting, antiseptic pretreatment before a subsequent VMT led to a 50% conversion rate, associated with an anti-inflammatory shift in gene expression. Metagenomic sequencing and strain-level genetic analysis confirmed donor engraftment in five of 10 women who showed microbiome conversion. Extensive exploration of the microbiome, immune response and metadata revealed differences in baseline energy metabolism in participants who later experienced donor engraftment. Treatments for vaginal dysbiosis are urgently needed and given that VMT can lead to donor engraftment and change the vaginal immune profile, future studies should focus on optimizing this treatment for various women’s health diseases.


  • Association between the length of in vitro embryo culture, mode of ART, and the initial endogenous hCG rise in ongoing singleton pregnancies

    by C Brockmeier, M B Borgstrøm, K Madsen, A Pinborg, N L Freiesleben, A Zedeler, M R Petersen, M L Grøndahl, P F Svendsen

    Is there an association between the length of in vitro culture, mode of ART and the initial endogenous hCG rise, in cycles with a foetal heartbeat after single embryo transfer (ET) and implantation? Both the length of in vitro culture and the mode of ART have an impact on the initial endogenous rise in hCG in singleton pregnancies. Different factors have been identified to alter the kinetics of hCG in pregnancies. Current studies show conflicting results regarding the kinetics of hCG after different types of ART (fresh vs frozen ET (FET)), the inclusion or not of preimplantation genetic testing (PGT), and the length of time in in vitro culture. This was a multicentre cohort study, using prospectively collected data derived from 4938 women (5524 treatment cycles) undergoing IUI (cycles, n = 608) or ART (cycles, n = 4916) treatments, resulting a in singleton ongoing pregnancy verified by first-trimester ultrasound scan. Data were collected from the Danish Medical Data Centre, used by the three participating Danish public fertility clinics at Copenhagen University hospitals: Herlev Hospital, Hvidovre Hospital, and Rigshospitalet, from January 2014 to December 2021. The fresh ET cycles included cleavage-stage (2 or 3 days in vitro) and blastocyst (5 days in vitro) transfers. FET cycles included cleavage-stage (3 days in vitro before cryopreservation) or blastocyst (5 or 6 days in vitro before cryopreservation) transfers. The IUI cycles represented no time in vitro. To attain a comparable interval for serum-hCG (s-hCG), the ovulation induction time was identical: 35–37 h before oocyte retrieval or IUI. The conception day was considered as: the insemination day for pregnancies conceived after IUI, the oocyte retrieval day for fresh ET, or the transfer day minus 3 or 5 as appropriate for FET of Day 3 or 5 embryos. Multiple linear regression analysis was used, including days post-conception for the hCG measurement as a covariate, and was adjusted for the women's age, the cause of infertility, and the centre. For FET, a sensitivity analysis was used to adjust for endometrial preparation. The study totally includes 5524 cycles: 2395 FET cycles, 2521 fresh ET cycles, and 608 IUI cycles. Regarding the length of in vitro culture, with IUI as reference (for no time in in vitro culture), we found a significantly lower s-hCG in pregnancies achieved after fresh ET (cleavage-stage ET or blastocyst transfer). S-hCG was 18% (95% CI: 13–23%, P < 0.001) lower after fresh cleavage-stage ET, and 23% (95% CI: 18–28%, P < 0.001) lower after fresh blastocyst transfer compared to IUI. In FET cycles, s-hCG was significantly higher after blastocyst transfers compared to cleavage-stage FET, respectively, 26% (95% CI: 13–40%, P < 0.001) higher when cryopreserved on in vitro Day 5, and 14% (95% CI: 2–26%, P = 0.02) higher when cryopreserved on in vitro Day 6 as compared to Day 3. Regarding the ART treatment type, s-hCG after FET blastocyst transfer (Day 5 blastocysts) cycles was significantly higher, 33% (95% CI: 27–45%, P < 0.001), compared to fresh ET (Day 5 blastocyst), while there was no difference between cleavage-stage FET (Days 2 + 3) and fresh ET (Days 2 + 3). S-hCG was 12% (95% CI: 4–19%, 0.005) lower in PGT FET (Day 5 blastocysts) cycles as compared to FET cycles without PGT (Day 5 blastocysts). The retrospective design is a limitation which introduces the risk of possible bias and confounders such as embryo score, parity, and ovarian stimulation. This study elucidates how practices in medically assisted reproduction treatment are associated with the hCG kinetics, underlining a potential impact of in vitro culture length and mode of ART on the very early embryo development and implantation. The study provides clinicians knowledge that the type of ART used may be relevant to take into account when evaluating s-hCG for the prognosis of the pregnancy. No funding was received for this study. AP has received consulting fees, research grants, or honoraria from the following companies: Preglem, Novo Nordisk, Ferring Pharmaceuticals, Gedeon Richter, Cryos, Merck A/S, and Organon. AZ has received grants and honoraria from Gedeon Richter. NLF has received grants from Gedeon Richter, Merck A/S, and Cryos. MLG has received honoraria fees or research grants from Gedeon Richter, Merck A/S, and Cooper Surgical. CB has received honoraria from Merck A/S. MB has received research grants and honoraria from IBSA. MPR, KM, and PVS all report no conflicts of interest. The study was registered and approved by the Danish Protection Agency, Capital Region, Denmark (Journal-nr.: 21019857). No approval was required from the regional ethics committee according to Danish law.


  • Open Access

    SARS-CoV-2 Antibodies in Breastmilk Three and Six Months Postpartum in Relation to the Trimester of Maternal SARS-CoV-2 Infection—An Exploratory Study

    by Line Fich, Ann-Marie Hellerung Christiansen, Anna Christine Nilsson, Johanna Lindman, Helle Gybel Juul-Larsen, Christine Bo Hansen, Nina la Cour Freiesleben, Mohammed Rohi Khalil, Henriette Svarre Nielsen

    The immune system of neonates is immature and therefore knowledge of possible early-life protection against SARS-CoV-2 infection, such as breastfeeding, is of great importance. Few studies have investigated the presence and duration of SARS-CoV-2 antibodies in breastmilk in relation to the trimester of maternal infection during pregnancy, and none with successful participation from all three trimesters. This study has dual objectives (1) in relation to the trimester of infection to examine the frequency, concentration and duration of IgA and IgG antibodies in breastmilk and blood serum in the third and sixth month post-partum in former SARS-CoV-2-infected mothers and (2) to examine the association in pediatric emergency admission of children within the first six months of life compared to children of non-SARS-CoV-2-infected women. The first objective is based on a prospective cohort and the second is based on a nested case–control design. The study participants are women with a former SARS-CoV-2 infection during pregnancy, whose serology IgG tests at delivery were still positive. Maternal blood and breastmilk samples were collected at three and six months postpartum. Serum IgA frequency three months pp was 72.7% (50%, 90% and 60% in the first, second and third trimester) and 82% six months pp (67%, 91% and 82% in the first, second and third trimester). Breastmilk IgA frequency three months pp was 27% (16.6%, 36% and 20% in first, second and third trimester) and 28% six months pp (0%, 38% and 28% in the first, second and third trimester). The highest IgA concentration in breastmilk was found six months post-partum with infection in the third trimester. Serum IgA was detectable more than 400 days post infection, and serum IgG above threshold was found 430 days after date of infection. We found no correlation between serum IgA and breastmilk IgA, nor between serum IgG and breastmilk IgA regardless of the trimester of infection.